BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration

MADISON, N.J.–(BUSINESS WIRE)–Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK), today announced the U.S. approval of BRAVECTO^® PLUS topical solution for cats by the U.S. Food and Drug Administration (FDA). BRAVECTO PLUS is an extended-duration, broad-spectrum combination (fluralaner and moxidectin) topical solution for cats, indicated for both external and internal parasite infestations: ticks and fleas, heartworm, intestinal roundworm and hookworm.

read more

Read Original Article: BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration »